Breast Cancer Panel Sequencing

Colorectal Cancer Panel Sequencing

Description of Breast Cancer

Breast cancer is one of the most numerous cancers in newly diagnosed cancer cases, and despite the decline in deaths, it still possesses the second mortality of cancer among women only after skin cancer. Especially, advanced breast cancer treatment is almost useless and can lead to disfigurement. Research suggests that one in every eight women in the United States has the risk of developing breast cancer. Abnormal nuclear DNA content and genetic alterations lead to an increase in the expression products of certain oncogenes and tumor suppressor genes. As a result, the phenotypic changes of some abnormal cells with a tendency to become cancerous are accumulated, which may lead to cancerization with the participation of internal and external promoting factors.

Breast cancer gene 1 (BRCA1), mapped to chromosome arm 17q, and it is reported about 45% of families with a high incidence of breast cancer have mutations in this gene. Moreover, about 80% of families with this mutation increase the risk of early-onset breast cancer and ovarian cancer. Breast cancer gene 2 (BRCA2), mapped to chromosome arm 13q, is also commonly found in early-onset breast cancer, with the mutation proportion roughly consistent with the BRCA1 gene. BRCA1 and BRCA2 which produce tumor suppressor proteins can help repair damaged DNA, and therefore, play an important role in cell cycle control. When either of these two genes is mutated or altered, the DNA may not be repaired completely. Cells may develop genetic alterations and even lead to cancer as a consequence.

CD Genomics utilizes targeted NGS sequencing technology to provide more efficient and accurate targeting of somatic and germline variants across BRCA1 and BRCA2 genes. If necessary, you can choose genes that fit your requirements.


Gene List of Breast Cancer Panel

BRCA1 BRCA2

Highlights of Breast Cancer Panel Sequencing Service

  • Target-enrichment sequencing by Illumina provides extremely high depth (average depth > 1000x) with lower costs.
  • High coverage uniformity ensures the sequencing data more efficiency.
  • SNVs, indels, and even low frequency variations can be detected.
  • Strict quality control throughout the pipeline workflow to ensure the accuracy and repeatability of the sequencing.
  • Fast turnaround time.

Applications of Breast Cancer Panel Sequencing

  • Disease predisposition
  • Therapeutic target discovery
  • Drug target discovery
  • Discover rare mutations and detect low frequency mutations

Service Specifications

Service Specifications

Sample Requirements

  • Sample types for genomic DNA from tissues, whole blood, saliva, formalin-fixed paraffin-embedded (FFPE) tissues.
  • Recommended amount: 2μg
  • Minimum amount: 200ng
  • Collection: DNA samples are stored in TE buffer or equivalent. Blood is collected by routine blood collection kits.
Service Specifications

Sequencing

  • Illumina PE150
  • Enrichment Method: Amplicon sequencing
  • More than 80% of bases with a ≥ Q30 quality score
  • Recommended sequencing depth: ≥ 5,000x
Service Specifications

Bioinformatics Analysis

We provide customized bioinformatics analysis including:

  • Read alignment
  • Variant calling/Annotation

Gene Panel Workflow

CD Genomics provides the accurate and cost-effective breast cancer panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for breast cancer panel sequencing is outlined below.

Gene Panel Workflow

Clinical Guidance on Gene Mutation by NCCN Guideline

Gene Targeted Drugs
BRCA1/2 Olaparib, Talazoparib

For more information about the breast cancer panel or need other amplification requirements, please contact us.

References:

  1. Tung N, et al. Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel. Cancer, 2015, 121(1).
  2. Easton D F, et al. Gene-panel sequencing and the prediction of breast-cancer risk. New England Journal of Medicine, 2015, 372(23): 2243-2257.
* For Research Use Only. Not for use in diagnostic procedures.

Online Inquiry
  • Please input "genomics" as verification code.

  • 45-1 Ramsey Road, Shirley, NY 11967, USA
  • 1-631-275-3058 (USA)
           44-208-144-6005 (Europe)
  • 1-631-614-7828
  • info@cd-genomics.com
Copyright © 2009 - 2020 CD Genomics. All rights reserved.
0
Inquiry Basket